This CPB has been revised to state that continuation of Prolia (denosumab) therapy is considered medically necessary for members (including new members) who are currently receiving the requested medication through a paid pharmacy or medical benefit and experiences clinical benefit after at least 12 months of therapy with denosumab as evidenced by improvement or stabilization in T-score. (Previous version stated clinical benefit after at least 24 months of therapy).